ライフサイエンスコーパス: controlled study

1 itivity analyses (eg, when excluding placebo-controlled studies).

2 domized, double-masked, multicenter, placebo-controlled study.

3 ter, open-label, dose-escalation, fellow-eye-controlled study.

4 as well tolerated in a double-blind, placebo-controlled study.

5 ase studies, cohort studies, and one placebo-controlled study.

6 ctive, double-blind, multicenter, randomized controlled study.

7 ctive, 1:1 randomized, double-blind, placebo-controlled study.

8 e, parallel-group, double-blind, randomized, controlled study.

9 dding in a randomized, double-blind, placebo-controlled study.

10 ansplantation were examined in a randomized, controlled study.

11 7.1 years) in a double-blind cross-over sham-controlled study.

12 This was a randomized, double-blind, placebo-controlled study.

13 drome in a randomised, double-blind, placebo-controlled study.

14 ults after 6 months has not been tested in a controlled study.

15 ns has not been assessed within a randomized controlled study.

16 lticenter, randomized, double-blind, placebo-controlled study.

17 om healthy donors in a double-blind, placebo-controlled study.

18 ed melanoma has not been tested in a phase 3 controlled study.

19 ntinuous levodopa delivery in a double-blind controlled study.

20 igraine in a phase 3 double-blind randomized controlled study.

21 patients enrolled in a double-blind, placebo-controlled study.

22 t of dTMS in a multicenter double-blind sham-controlled study.

23 rofile consistent with those seen in placebo-controlled studies.

24 res are frequently conducted without closely controlled studies.

25 logical credibility and warrants randomized, controlled studies.

26 impact in drug binding sites merits further controlled studies.

27 on anecdotal cases rather than on randomized controlled studies.

28 ) and 15 (36.6%), respectively, were vehicle-controlled studies.

29 ck needs to be studied in further randomized controlled studies.

30 e-blind, parallel-group, placebo- and active-controlled studies.

31 vir; it is now being evaluated in additional controlled studies.

32 are not consistently confirmed in larger and controlled studies.

33 indings between observational and randomized controlled studies.

34 ing a conductivity/Seebeck vise for pressure-controlled studies.

35 removed from the tokamak for post-mortem and controlled studies.

36 In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-phosphate

37 In a randomized double-blind placebo-controlled study, 56 patients with moderate-severe LAR t

38 In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years with al

39 lticenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (a

40 s 12-wk, double-blinded, randomized, placebo-controlled study, 76 vegans received either a placebo (n

41 In controlled studies, a single springtime application of a

42 In a double-blind placebo-controlled study, adult participants (18-65 years old) w

43 lticentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non

44 In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent

45 a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were

46 en 1970 and 2019 for randomised or otherwise controlled studies and observational cohort studies.

47 iac surgery by a meta-analysis of randomized controlled studies and observational studies.

48 rane conductance regulator (CFTR) in placebo-controlled studies and patients aged 6-11 years with cys

49 followed up prospectively in the randomized controlled study and thereafter were followed up in ordi

50 There were few controlled studies, and control for confounding was inad

51 -1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised,

52 Larger controlled studies are essential to prove efficacy

53 n the current body of literature, large well-controlled studies are necessary to better quantify the

54 Prospective controlled studies are necessary to confirm the benefici

55 of our findings on Plasmodium transmission, controlled studies are needed in participants with gamet

56 Larger placebo-controlled studies are needed to fully assess efficacy.

57 Controlled studies are needed to substantiate findings.

58 food allergy is not clear, and more placebo-controlled studies are needed.

59 Larger randomized controlled studies are required to confirm these results

60 More data from randomized controlled studies are warranted.

61 Further controlled studies are warranted.

62 entions and rates of breastfeeding from well-controlled studies as well as for harms related to breas

63 This phase 1 placebo-controlled study assessed safety and immunogenicity of t

64 study, a multicentre, open-label, randomised controlled study at 19 specialist paediatric surgery cen

65 a 36-week randomised, double-blind, placebo-controlled study at 25 centres in the USA.

66 We did this double-blind, placebo-controlled study at 35 hospitals in Canada, France, Germ

67 parallel, randomised, double-blind, placebo-controlled study at 37 sites (hospitals and specialty cl

68 mised, double-blind, parallel-group, placebo-controlled study at 49 hospitals in seven European count

69 e complexity of the disease and the very few controlled studies available.

70 In this first placebo-controlled study, canakinumab was effective in patients

71 lusion: In this 12-week, randomized, placebo-controlled study, cilofexor was well tolerated and led t

72 edline, PubMed, Cochrane Central Register of Controlled Studies, CINAHL Plus, AMED, EMBASE and HuGE N

73 Eight controlled studies compared the effectiveness of no IVC

74 ulation of lipolysis.A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosapentaenoic

75 review was conducted to identify randomized controlled studies comparing nurse-led self-management i

76 ating in a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT antepartum ve

77 after 6 months in a prospective, randomised, controlled study comparing best medical therapy (BMT, n=

78 We performed a prospective, randomized controlled study comparing operator radiation dose durin

79 In two multicenter, crossover, randomized, controlled studies conducted under free-living home cond

80 ine, was assessed in a double-blind, placebo-controlled study conducted from September 2014 to April

81 ssed in a multicentre, double-blind, placebo-controlled study conducted in 483 patients with BP-induc

82 That nested-case controlled study consisted of specimens specifically cho

83 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with >/=4 a

84 A previous randomized, placebo-controlled study demonstrated that grass allergen peptid

85 This large, prospective, randomized, controlled study demonstrates noninferiority of CB ablat

86 e first multicenter, randomized, masked, and controlled study demonstrating the ERL is not inferior t

87 er using a monocenter, double-blind, placebo-controlled study design.

88 This prospective randomized controlled study (DISCOVER trial) included 152 patients

89 e weaker in actual clinical practice than in controlled studies, dissipate following treatment for ab

90 Dropout rates in sublingual immunotherapy controlled studies do not appear to be a major problem w

91 three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA, UK, Cana

92 a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countries (Arg

93 -IIP was a double-blind, randomised, placebo-controlled study done at 65 pulmonary hypertension and i

94 omised, parallel group, double-blind, active-controlled study done in 159 sites across 14 countries.

95 lticentre, double-blind, randomised, placebo-controlled study done in 48 acute care hospitals in eigh

96 phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we rando

97 se concentration in 2 randomized, crossover, controlled studies (double-blinded for the supplements),

98 In this open-label, randomised, controlled study, eligible healthy infants 6-12 weeks of

99 s phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with

100 ods: This prospective, double-blind, placebo-controlled study enrolled 10 patients with biochemically

101 lticenter, randomized, double-blind, placebo-controlled study evaluated 3 regimens of grass allergen

102 domized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine ag

103 This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmac

104 This phase 1/2, randomized, placebo-controlled study evaluated the immunogenicity and safety

105 This phase III, randomized, placebo (saline)-controlled study evaluated the safety of rhC1INH 50 IU/k

106 Randomized, controlled studies evaluating the safety and efficacy of

107 ECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin

108 tudy is an adaptive, open-label, randomized, controlled study evaluating whether autonomic regulation

109 There are limited well-controlled studies examining the effectiveness of system

110 -D cell oncology models and allow for better-controlled studies for drug discovery.

111 arried out a double-blind randomized placebo-controlled study for 16 weeks, followed by an open-label

112 red trial, we designed this first randomized controlled study for the comparison of TVC and NC.

113 The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disability o

114 controlled trials and prospective randomised controlled studies) from cohorts including European, Ame

115 We conducted a parallel controlled study, from July 2016 through January 2018 at

116 tive method for preventing infection, but no controlled study has been published in the United States

117 To our knowledge, this is the first time a controlled study has demonstrated a survival advantage i

118 A new randomized, double-blind controlled study has found that playing a video game mod

119 A number of placebo-controlled studies have been completed or are underway u

120 Few well-controlled studies have comprehensively examined the eff

121 Several controlled studies have confirmed that an intense approa

122 However, controlled studies have demonstrated antidepressant acti

123 Numerous placebo-controlled studies have demonstrated the ability of keta

124 al disease in young children, but no matched controlled studies have evaluated it.

125 However, some well-controlled studies have found regionally greater gray ma

126 Several randomised placebo-controlled studies have shown that UDCA improves transpl

127 phase 1, double-blinded, randomized, placebo-controlled study, healthy subjects were inoculated intra

128 re included in this single-mask, randomized, controlled study if probing depth (PD) was </=3 mm and a

129 Findings should be validated in larger, controlled studies in animals and humans using a range o

130 ave employed uncontrolled field experiments, controlled studies in experimental streams, and laborato

131 performed a blinded, randomized and placebo-controlled study in 11 conscious patients (nine men, two

132 multihospital, multidepartmental prospective controlled study in an urban academic setting.

133 In summary, this is the first prospective, controlled study in CLL patients that shows a role of co

134 lticentre, double-blind, randomised, placebo-controlled study in four hospitals in Kenya (two rural h

135 In a double-blind, placebo-controlled study in healthy adults experimentally infect

136 lticenter, randomized, double-blind, placebo-controlled study in patients with biopsy-confirmed nonal

137 , phase 3, randomised, double-blind, placebo-controlled study in patients with tuberous sclerosis com

138 We did a cluster-randomised, blinded, controlled study in three villages in India.

139 We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behcet's syn

140 This was a randomized, double-blind, placebo-controlled study in which 68 individuals were randomly a

141 an open-label, randomised, active-comparator controlled study, in which participants were inoculated

142 ospective, randomized, double blind, placebo-controlled study included 30 patients randomised with a

143 A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (

144 This randomized, double-blind, controlled study included Canadian and Spanish patients

145 A number of well-controlled studies indicate that probiotics, particularl

146 , phase 2, randomized, double-blind, placebo-controlled study investigated the safety, tolerability,

147 -in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability,

148 alysis Patients), a prospective, randomized, controlled study investigating the value and safety of I

149 This cluster-randomized controlled study involved 15 Head Start preschools in Ha

150 port an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel amino

151 a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open label e

152 lticenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the

153 e conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously trea

154 ng novel vaccines in the human population in controlled studies is difficult due to the limited avail

155 Replication of such results in well controlled studies is essential to clarify the effects o

156 t evidence from natural experiments or other controlled studies is scarce.

157 results can be confirmed by larger and well-controlled studies, it may have considerable programmati

158 For music interventions, we pooled controlled studies measuring health outcomes (eg, pain,

159 ed from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week treatmen

160 above mainly because there is a lack of well-controlled studies, most information comes from small st

161 Within a randomized double-blind placebo-controlled study (n = 115), we examined whether leukocyt

162 In a cross-sectional controlled study, nasal fluid and sera were collected du

163 We did two double-blind, active-controlled studies (now in open-label extension phase).

164 , from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration (NCT010

165 om-nanophotonic systems, as well as enabling controlled studies of atom-surface interactions at the n

166 Few long-term or controlled studies of bariatric surgery have been conduc

167 h meta-analysis, randomized or nonrandomized controlled studies of conservative endometriosis surgery

168 Few controlled studies of in-store marketing strategies to p

169 Controlled studies of patients receiving enteral nutriti

170 led from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the two CAPAC

171 Cohort and case-controlled studies of pregnant women have demonstrated p

172 To our knowledge, no controlled studies of the effects of long-term growth ho

173 There have been few controlled studies of these therapies, which have been l

174 We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe C

175 ndomized Phase I/II, observer-blind, placebo-controlled study of 12 healthy, H pylori-negative adults

176 d emergence of antimicrobial resistance in a controlled study of 149 newborn infants recruited within

177 fteen participants with atopy completed this controlled study of 2 hours of filtered air or DE (300 m

178 This is a prospective, randomized, controlled study of 26 patients treated at a tertiary ca

179 rticipants: Multicenter double-blind placebo-controlled study of 260 nonneutropenic, nontransplanted,

180 I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac su

181 1, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac su

182 erformed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarrhea or a

183 nonlesional skin in a double-blind, placebo-controlled study of 54 patients with moderate to severe

184 embers of the dyad.We conducted a randomized controlled study of 97 mother-infant dyads.

185 id a nationwide, prospective, non-randomised controlled study of adolescents (aged 13-18 years) with

186 from 386 patients enrolled in a randomized, controlled study of antibiotic efficacy.

187 This work will enable future temperature controlled study of biomolecular complex at the single m

188 acy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy and 4 t

189 In a randomized controlled study of consecutive patients undergoing ERCP

190 The results of this first randomized controlled study of DBS for the treatment of TRD did not

191 nitiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC.

192 reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT) in whi

193 We used real-world data from a large biopsy-controlled study of excessive drinkers recruited from pr

194 opulation is limited, we conducted the first controlled study of imitation in AS.

195 Furthermore, controlled study of infection has been hampered by the l

196 The authors conducted a sham-controlled study of iTBS for PTSD.

197 of life.A double-blind, randomized, placebo-controlled study of newborn infants assigned to a standa

198 work in a randomized, double-blind, placebo-controlled study of patients with bipolar depression.

199 ndertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcino

200 In a placebo-controlled study of patients with IBS, a low FODMAP diet

201 in the CRITICS trial, a phase III randomized controlled study of perioperative treatment in patients

202 000 g) participating in a randomized placebo-controlled study of probiotic supplementation.

203 F were enrolled in a multicenter, randomized controlled study of PV isolation using either the VGLB o

204 We conducted a case-controlled study of the associations of CCR5-Delta32 het

205 We believe that this is the first carefully controlled study of the behaviour of birds in response t

206 d, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg an

207 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of T

208 r diseases; however, results from randomized controlled studies on blood lipids are inconsistent, pot

209 Controlled studies on the effect of neurosurgical treatm

210 An additional randomized, crossover, controlled study on 16 volunteers consuming constituent

211 We conducted a double-blind sham-controlled study on 20 human volunteers (10 females) usi

212 Two retrospective, controlled studies, one uncontrolled study and 79 case r

213 omised, double-blind, parallel-group, active-controlled study, patients aged 18 years or older with A

214 s phase 2A double-blind, randomised, placebo-controlled study, patients aged 18 years or older with c

215 No controlled studies pertaining to tooth sites were identi

216 In this controlled study population of patients with retinoblast

217 In addition, vehicle- or placebo-controlled studies predominate over head-to-head compari

218 2) Forty-five controlled studies provided outcome analysis on the use

219 A mix of anecdotal and more controlled studies provides some support for this view;

220 This large randomized controlled study provides strong support for the efficac

221 We only included randomised controlled studies published in English evaluating the i

222 his was a multicenter, double-blind, placebo-controlled study randomizing subjects to 12 weeks of tre

223 We did a multicentre, double-blind, placebo-controlled study (RESILIENT) at 38 academic clinical sit

224 rt, parallel group, double-blind, randomised controlled studies, reSURFACE 1 (at 118 sites in Austral

225 Larger, randomized controlled studies should be performed to further guide

226 Further controlled studies should evaluate its efficacy and safe

227 vertheless, early enthusiasm was tempered by controlled studies showing that antibiotics did not serv

228 This randomized controlled study shows that a 45 W radiofrequency power

229 Initial data from a placebo-controlled study suggest faster time to recovery in pati

230 The results of our randomized, crossover, controlled study suggest that 3 wk of sustained nutritio

231 IGNIFICANCE STATEMENT This double-blind sham-controlled study suggested that neurofeedback training c

232 saline-controlled studies than in midazolam-controlled studies (t(276) = 2.32, p = 0.02).

233 The authors conducted a review of randomized controlled studies testing the efficacy of adding a beha

234 The authors conducted a review of randomized controlled studies testing the efficacy of adding a beha

235 ine relative to control was larger in saline-controlled studies than in midazolam-controlled studies

236 We searched multiple databases for controlled studies that enrolled pregnant women with chr

237 o phase 3, randomized, double-blind, placebo-controlled studies that utilized the same sequential par

238 o phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effe

239 We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety

240 Here, we report a double-blind, placebo-controlled, study that examined specific effects of nora

241 In this placebo-controlled study, the authors tested the cognitive benef

242 This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over two poll

243 educe reliability and conduct more carefully controlled studies to improve reliability.

244 We performed a randomized, placebo-controlled study to determine its effects on symptoms an

245 We performed a large, multicenter randomized controlled study to determine the comparative efficacy o

246 We performed a placebo-controlled study to determine whether a delayed-release

247 onducted a double-blind, randomized, placebo-controlled study to evaluate the effect of gallopamil on

248 a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of

249 RYTON (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness

250 (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness

251 re, we report the first double-blind placebo-controlled study to examine the effects of MDMA on emoti

252 d a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients

253 We performed a meta-analysis, which included controlled studies, to assess the relative risk of these

254 This prospective controlled study took place at a clinical research cente

255 This prospective controlled study took place at an academic research cent

256 Of five randomised controlled studies, two showed significantly higher quit

257 In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Austr

258 We performed a randomized, placebo-controlled study using C1-INH in highly sensitized renal

259 this interaction, we conducted a randomized controlled study using the baboon (Papio anubis) to anal

260 A systematic review of randomized controlled studies was conducted.

261 A single-center parallel-group randomized controlled study was completed.

262 domized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in four cou

263 prospective, single-center, cross-sectional controlled study was conducted at the French National Re

264 This prospective interocularly controlled study was conducted between February 1 and De

265 prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects from Lati

266 Thus, this longitudinally controlled study was conducted in 4-month old (equivalen

267 Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet adm

268 This phase 3, double-blind, placebo-controlled study was done at 118 sites in 13 countries a

269 This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America,

270 This randomised, double-blind, placebo-controlled study was done by movement disorder specialis

271 This phase 1, randomised, placebo-controlled study was done in two parts.

272 ulticenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficac

273 The aim of this prospective randomized controlled study was to evaluate the safety and effectiv

274 im of this randomized, double-blind, placebo-controlled study was to test the hypothesis that anodal

275 In this randomized controlled study, we aimed to determine whether a high-e

276 lticenter, randomized, double-blind, placebo-controlled study, we assessed larazotide acetate 0.5, 1,

277 lticentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years

278 In a prospective, parallel-group, randomized controlled study, we examined the effect of 2 years of h

279 In this randomized, controlled study, we investigated the effects of lowerin

280 In this double-blind, placebo-controlled study, we investigated whether a single 10 mg

281 In this randomized, double-blind, placebo-controlled study, we randomly assigned 32 HSCT recipient

282 is phase 3, multicentre, randomised, placebo-controlled study, we randomly assigned adults with HCV g

283 In this phase 2, controlled study, we randomly assigned patients with acq

284 In this multicenter randomized controlled study, we randomly assigned patients with loc

285 his phase 2 randomised, double-blind placebo-controlled study, we recruited healthy adults (>=18 year

286 s (SCIMITAR+) trial, a pragmatic, randomised controlled study, we recruited heavy smokers with bipola

287 In this multicentre, randomised, controlled study, we recruited patients from three diabe

288 single-centre (Leicester, UK), prospective, controlled study, we selected cases of natural and non-s

289 In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of c

290 In a placebo-controlled study, we used arterial spin labeling to meas

291 Randomized controlled studies were utilized when available; however

292 limitations, knowing that further randomized controlled studies will be required before the approval

293 A sequential gatekeeping strategy controlled study-wise type 1 error for serum ferritin, t

294 c populations have been tested in randomised controlled studies with age-appropriate cohorts.

295 animals is less invasive and enables better-controlled studies with more immediate translation to th

296 We conducted a case-controlled study with 106 obese patients with cirrhosis

297 We designed a prospective controlled study with 2 sequential cohorts of participan

298 olled in a double-blind, randomized, placebo-controlled study with pexacerfont (300 mg/day for 7 days

299 his hypothesis via a double-blinded, placebo-controlled study with the dopamine receptor agonists cab

300 Very few prospective controlled studies, with limited quality of evidence, ex